NASDAQ$GHRS
GH Research PLC · Q2 2026 earnings
Q2 2026 earnings · · Before market open · Investor relations
Briefing
GH Research PLC reported Q2 2026 financial results showing a net loss of $15.1 million amid continued Phase 3 preparations for GH001.
The clinical-stage biopharmaceutical company reported no revenue for the quarter ended June 30, 2026. R&D expenses rose to $12.4 million and G&A to $7.1 million, resulting in a net loss of $15.1 million ($0.23 per share). Cash, cash equivalents and marketable securities reached $362.7 million following a $117.5 million equity offering.
- Net loss of $15.1 million ($0.23 per share) for Q2 2026, up from $9.3 million ($0.15 per share) in Q2 2025.
- Cash position strengthened to $362.7 million as of June 30, 2026, boosted by $117.5 million gross proceeds from underwritten offering.
- R&D expenses increased to $12.4 million and G&A to $7.1 million, reflecting expanded clinical development.
- FDA confirmed CMC and device plans appear Phase 3 ready; company targets initiation of global pivotal program for GH001 in TRD in 2026.
Headline financials
Revenue & EPS history
GH Research · Revenue · Quarterly
$0
Forward guidance
Company targets initiation of global Phase 3 pivotal program for GH001 in TRD in 2026 following FDA feedback on CMC and device plans.
Tailwinds
- FDA written responses confirm CMC and device plans appear Phase 3 ready
- Completed Phase 1 trials GH001-HV-106 and GH001-HV-109; doses selected for pivotal program
- Strengthened IP with new U.S. patent to 2043 and maintained EU patent to 2040
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports
+0.7%
Avg return
Earnings day
+1.4%
Avg return
5 days after
+0.3%
Avg return
30 days after
55%
6 / 11 earnings
Positive
+24.4%
Q3 2021
Best reaction
-19.3%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | +1.3% | +0.2% | -3.7% | |
| Q3 2025 | -1.2% | +4.6% | +9.6% | |
| Q4 2025 | -4.8% | -10.2% | -21.6% | |
| Q2 2025 | +2.2% | +10.2% | +19.3% | |
| Q4 2024 | -2.9% | -14.4% | +0.8% | |
| Q2 2024 | -19.3% | -21.6% | -37.8% | |
| Q1 2024 | +4.5% | +7.1% | +25.9% | |
| Q2 2023 | -5.8% | +1.2% | -5.0% | |
| Q1 2023 | +8.2% | +6.9% | +24.6% | |
| Q4 2021 | +1.1% | +7.5% | -15.6% | |
| Q3 2021 | +24.4% | +24.4% | +7.1% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro